Indivior Pharmaceuticals (INDV) EBITDA (2024 - 2026)

Indivior Pharmaceuticals' EBITDA history runs 3 years deep, the most recent figure standing at $137.0 million for Q1 2026.

• In Q1 2026, EBITDA rose 179.59% year-over-year to $137.0 million; the TTM figure through Mar 2026 stood at $281.0 million (up 751.52% YoY), while the FY2025 annual figure was $262.0 million, up 589.47% from the prior year.
• EBITDA was $137.0 million for Q1 2026 at Indivior Pharmaceuticals, up from $81.0 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of $137.0 million in Q1 2026 to a low of -$97.0 million in Q2 2024.
• Historically, EBITDA has averaged $41.4 million across 3 years, with a median of $46.0 million in 2024.
• The sharpest annual moves came in 2025 and 2026: EBITDA declined 16.95% in 2025, then soared 179.59% in 2026.
• A 3-year view of EBITDA shows it stood at $46.0 million in 2024, then surged by 76.09% to $81.0 million in 2025, then surged by 69.14% to $137.0 million in 2026.
• The last three EBITDA figures came in at $137.0 million (Q1 2026), $81.0 million (Q4 2025), and $43.0 million (Q3 2025), per Business Quant data.